Preliminary clinical experience with BRAF inhibitors, including our group’s work, either as a monotherapy or in combination with MEK inhibitors, has already yielded encouraging results in ameloblastomas [15, 33, 34]. This evidence concerns the gene MAP2K7 and ameloblastoma.